US Edition
News from lifesciencesbc.ca
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top lifesciencesbc.ca News
Health Canada · CanadaHealth Canada has approved the first drug designed to treat postpartum depression.Zuranolone, sold under the brand name Zurzuvae, is a pill taken once a day for 14 days and can start relieving depressive symptoms in as few as three days.Manufactured by Biogen, the drug has been approved for use in the United States since late 2023 and is also authorized in the U.K. and the European Union.See the Story
Health Canada approves 1st pill to treat postpartum depression
73% Left coverage: 26 sources
MedicalPatients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hemat…See the Story
Tec-Dara Could Represent a New Standard of Care for Relapsed or Refractory Multiple Myeloma
100% Center coverage: 4 sources
